Baxter International Inc. (BAX) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Stable cash flow, improving free cash flow, and operational efforts counterbalance ongoing product setbacks and legal risks; near-term valuation pressures and technical downtrend limit short-term upside, advising caution despite healthcare sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High leverage ⢠EBITDA deterioration BAX has solid liquidity and free cash flow but is highly leveraged with large intangibles and a sharp recent deterioration in profitability, making it a risky turnaround candidate.
Price Behavior
Key Price Behavior Insights: ⢠Accelerating decline ⢠Support breakdown ⢠Resistance rejections Support Level: $19.50â$20.50; $17.69 Resistance Level: $21.70â$21.90 BAX is in a clear short-term downtrend over the last month, losing roughly 18â19% to a new low and breaking 19.5â20.5 support, with 21.7â21.9 acting as a firm resistanceâpotentially oversold and vulnerable to a relief bounce if momentum/volume stabilizes.
Sentiment & News
Key News Insights: ⢠Earnings miss ⢠Guidance cut ⢠Investor flight Baxter faces short-term execution and margin pressure after an earnings miss, lowered FY26 guidance tied to hurricane disruption, leadership changes and investor skepticism that sent shares sharply lower.
AI Summary
Baxter has shifted from a steady medâtech cashâflow story to a highâvariance turnaround where timely Novum IQ LVP remediation and rapid, FCF-driven deleveraging are the decisive catalystsâif remediation or IVâvolume normalization slips, elevated leverage and legal exposures are likely to precipitate material downside, so model multiple stress scenarios and monitor remediation milestones, quarterly free cash flow, and netâleverage progress closely.
Description
Baxter International Inc. develops and supplies a broad range of healthcare products and therapies globally, including renal care (peritoneal, hemodialysis and continuous renal replacement), intravenous and infusion systems, parenteral nutrition, surgical hemostasis and adhesion prevention devices, and critical care and respiratory technologies. Its portfolio also includes connected care and monitoring solutions, surgical equipment and contracted services for pharmaceutical and biopharmaceutical customers. The company distributes through a direct sales force, distributors, wholesalers and specialty pharmacies across roughly 100 countries and is headquartered in Deerfield, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 8 | Dec 15 | BAX | Baxter International Inc. | Stable cash flow, improving free cash flow, and operational efforts counterbalance ongoing product setbacks and legal risks; near-term valuation pressures and technical downtrend limit short-term upside, advising caution despite healthcare sector tailwinds. | Closed | +7.5% |